Play

CAR-T therapy, where someone’s own immune cells are trained to go after their cancer, has now been shown to confer a heightened infection risk, and risk of death from infection, for some recipients. Johns Hopkins Kimmel Cancer Center director William …

How does infection risk relative to CAR-T treatment factor into therapy? Elizabeth Tracey reports Read more »

Play

Just keeping up with the names is difficult: fentanyl, carfentanyl, xylazine, now nitazines…and each has a host of harms and is more potent than its predecessor. Substance use disorder expert Eric Strain at Johns Hopkins says keeping up is a …

How is it that more and more powerful opioids are appearing among street drugs? Elizabeth Tracey reports. Read more »

Play

Adding the potent opioid nitazine to heroin or fentanyl is hard to understand, since it ups the likelihood you’ll kill your clientele. Eric Strain, a substance use disorder expert at Johns Hopkins, is nonplussed. Strain: Why? That's a great question …

Why add even more potent synthetic opioids to existing ones? Elizabeth Tracey reports Read more »

Play

When someone is brought to the ED having overdosed, the clock is ticking to identify what substance they’ve used and then attempt to reverse it. Johns Hopkins substance use disorder expert Eric Strain says that’s why the new street opioid …

What are the dangers of nitazines? Elizabeth Tracey reports Read more »

Play

No sooner does awareness of new types of street opioids develop than the next generation appears. Such is the case with nitazines, a class of opioids being found increasingly adulterating heroin and fentanyl, with deadly consequences. Johns Hopkins substance use …

Newer and more potent street opioids are always being developed, Elizabeth Tracey reports Read more »

Play

First was heroin, then came fentanyl and its variations, then came xylazine. Now nitazines, a class of drugs that augment the action of opioids, are being found in drugs trafficked illegally, and they’re deadly. Eric Stain, a substance use disorder …

There’s a new drug being added to opioids bought on the street, Elizabeth Tracey reports Read more »

Play

Most clinicians know that depression, anxiety and other mood disorders are treatable conditions. Unfortunately, clinicians often face barriers when accessing care for themselves. To better understand why, we welcome Dr. Karen Swartz, Professor of Clinical Psychiatry at Johns Hopkins to …

Ep. 6 — “I should be able to manage this myself”:  The unique challenges of getting clinicians to access mental health care | Johns Hopkins Medicine Office of Well-Being Read more »